- Stocks
- Pharma & Healthcare
- Orchid Pharma
Orchid Pharma share price
NSE: ORCHPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Orchid Pharma at a glance
Orchid Pharma (NSE: ORCHPHARMA) closed at ₹891.00 on 19 Oct 2026, down 1.98% on the day. With a market capitalisation of ₹4,519 Cr, it ranks 834th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 217.8× trailing earnings, against a return on equity of 1.6% in FY26. Over the past year the share price has risen 19.3%. Its 52-week range is ₹480.00 (30 Mar 2026) to ₹1,143.50 (22 Sep 2026); the last close is 22.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹238 Cr (+0.1% year on year) and net profit ₹23 Cr (+19.1%), on a consolidated basis. Promoters held 69.84% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,519 CrRank 834 on NSE
- P/E (trailing)
- 217.8×
- Price to book
- 1.88×FY26
- EPS (TTM)
- ₹4.01to Q4 FY26
- ROE
- 1.6%FY26
- ROCE
- 2.5%FY26
- Debt to equity
- 0.28FY26
- Net profit margin
- 2.6%FY26
- Book value / share
- ₹253.91FY26
- 52-week high
- ₹1,143.5022 Sep 2026
- 52-week low
- ₹480.0030 Mar 2026
- 1-year return
- +19.3%
- RSI (14-day)
- 32.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.98% | −8.6% | −7.5% | −14.9% | +19.3% |
Orchid Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹244 Cr | ₹223 Cr | ₹217 Cr | ₹237 Cr | ₹173 Cr | ₹194 Cr | ₹207 Cr | ₹238 Cr |
| Revenue YoY | +33.6% | +12.0% | −1.5% | +9.4% | −29.2% | −13.1% | −4.6% | +0.1% |
| Net profit | ₹28 Cr | ₹26 Cr | ₹22 Cr | ₹19 Cr | ₹14 Cr | −₹3 Cr | −₹12 Cr | ₹23 Cr |
| Net profit YoY | +162.2% | +29.4% | −25.6% | −42.9% | −51.5% | −112.9% | −154.1% | +19.1% |
| Net margin | 11.6% | 11.6% | 10.3% | 8.1% | 7.9% | −1.7% | −5.9% | 9.6% |
| EPS | ₹5.79 | ₹5.37 | ₹4.10 | ₹4.40 | ₹2.94 | −₹1.13 | −₹2.49 | ₹4.69 |
Orchid Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹450 Cr | ₹560 Cr | ₹666 Cr | ₹819 Cr | ₹922 Cr | — |
| Operating profit | −₹95 Cr | −₹57 Cr | ₹16 Cr | ₹92 Cr | ₹96 Cr | — |
| Net profit | −₹117 Cr | ₹2 Cr | ₹48 Cr | ₹95 Cr | ₹96 Cr | — |
| EPS (₹) | −₹29.00 | ₹0.00 | ₹11.00 | ₹19.00 | ₹20.00 | — |
| Cash from operations | ₹24 Cr | ₹92 Cr | ₹18 Cr | ₹126 Cr | ₹19 Cr | — |
| Total debt | ₹428 Cr | ₹208 Cr | ₹149 Cr | ₹120 Cr | ₹132 Cr | ₹328 Cr |
| Shareholders' equity | ₹653 Cr | ₹647 Cr | ₹689 Cr | ₹1,169 Cr | ₹1,267 Cr | ₹1,288 Cr |
Orchid Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| Foreign institutions | 2.69% | 1.40% | 1.56% | 1.17% | 0.87% | 0.81% |
| Domestic institutions | 20.10% | 19.43% | 19.04% | 19.39% | 20.25% | 20.75% |
| Non-institutions | 7.38% | 9.34% | 9.57% | 9.60% | 9.05% | 8.61% |
Orchid Pharma vs peers
The listed Pharma & Healthcare companies nearest to Orchid Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NOVARTINDNovartis India | ₹1,919.80 | +2.07% | +245.9% | ₹4,740 Cr | 50.9 | — |
| ZOTAZota Health Care | ₹1,361.00 | −2.51% | −7.1% | ₹4,713 Cr | — | — |
| RPGLIFERPG Life Sciences | ₹2,849.00 | −2.60% | +22.6% | ₹4,712 Cr | 40.9 | — |
| JSLLJeena Sikho Lifecare | ₹367.20 | −5.77% | −51.9% | ₹4,564 Cr | 20.7 | — |
| ORCHPHARMAOrchid Pharma | ₹891.00 | −1.98% | +19.3% | ₹4,519 Cr | 217.8 | — |
| GUFICBIOGufic Biosciences | ₹404.00 | +0.50% | +10.7% | ₹4,051 Cr | 63.1 | — |
| SMSPHARMASMS Pharmaceuticals | ₹432.55 | −3.90% | +57.6% | ₹4,051 Cr | 38.8 | — |
Ask anything about Orchid Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against ORCHPHARMA's own history. Try: “Why has ORCHPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on ORCHPHARMA over five years” · “Compare ORCHPHARMA with NOVARTIND on margins and valuation”
Frequently asked questions about Orchid Pharma
What is the share price of Orchid Pharma today?
Orchid Pharma (NSE: ORCHPHARMA) last closed at ₹891.00 on 19 Oct 2026. Its 52-week high is ₹1,143.50 and its 52-week low is ₹480.00.
What is the market cap of Orchid Pharma?
Orchid Pharma's market capitalisation is ₹4,519 Cr (₹4,519 Cr) at the 19 Oct 2026 close, ranking 834th among the NSE companies Pivot tracks.
What is the P/E ratio of Orchid Pharma?
Orchid Pharma trades at a trailing P/E of 217.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 40.9.
What is the ROE and ROCE of Orchid Pharma?
Return on equity was 1.6% in FY26 and return on capital employed was 2.5% in FY26 (consolidated figures).
Is Orchid Pharma a debt-free company?
No. Orchid Pharma's debt-to-equity ratio was 0.28 in FY26, with total debt of ₹328 Cr.
What were Orchid Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Orchid Pharma reported revenue of ₹238 Cr, +0.1% year on year, and net profit of ₹23 Cr, +19.1% year on year.
How has Orchid Pharma stock performed over the last year?
Orchid Pharma's share price has risen 19.3% over the past year, −14.9% over three months and −7.5% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Orchid Pharma?
As of 30 Jun 2026: promoters 69.84%, foreign institutions 0.81%, domestic institutions 20.75%, non-institutions 8.61%.
Who are Orchid Pharma's competitors?
The listed Pharma & Healthcare companies closest to Orchid Pharma by market cap are Novartis India, Zota Health Care, RPG Life Sciences, Jeena Sikho Lifecare, Gufic Biosciences and SMS Pharmaceuticals.
Is Orchid Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Orchid Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ORCHPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with O · all NSE stocks · this page as text